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1. Background
ypertension (HTN) is a very common dis-
order with a substantial impact on pub-
lic health because of  its complications. 
Despite the high prevalence of  essential hyper-
tension (eHTN) and many researches, the basic 
causes remain unclear (1-2). Serum lipoprotein(a) 
[Lp(a)] is a complex lipoprotein particle which 
has homology structure with plasminogen of  
the ﬁbrinolytic system (3). Little is known about 
the association of  serum Lp(a) elevation with es-
sential hypertension , while  in vitro experiments 
have shown that oxidized Lp(a) is able to impair 
the arterial endothelium – dependent dilation, 
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thus suggesting a possible role of  Lp(a) in the 
genesis of  eHTN (4).
2. Objectives
 Few studies have shown elevated level of  LP 
(a) in eHTN, however, results are controversial 
(4, 5). Therefore, the aim of  our study was to 
measure the serum concentrations of  Lp (a) in a 
group of  essential hypertensive patients with no 
clinical signs of  organ damage.
3. Patients and Methods
 This cross-sectional study was carried out on 
a group of  essential hypertensive (eHT) patients 
who were documented by history, physical exam-
ination and laboratory tests. Factors served as ex-
clusion criteria were cigarette smoking, anti-lipid 
drug taking, antihypertensive or any drug affect-
ing lipids proﬁles. Also presence of  diabetes mel-
litus, recent MI and vascular diseases, presence of  
acute or chronic infections were other exclusion 
criteria.
 For all the patients, laboratory tests consist-
ing of  lipid proﬁles, serum  creatinine were per-
formed after 14 hours fasting. For all subjects 
serum Lp(a) was  measured through enzyme im-
muno assay (ELISA) with  Immuno-Biological 
Laboratories (IBL) kit of  Hamburg. Normal 
values for Lp(a) in this study were the ones up 
to 39 mg/dL. Estimated glomerular ﬁltration 
rate (eGFR) was calculated from serum creati-
nine, age and body weight. For stratiﬁcation of  
hypertensive patients according to the report of  
the joint national committee on prevention, de-
tection, evaluation and treatment of  high blood 
pressure we stratiﬁed hypertensive  patients from 
stage one to three (5). For statistical analysis de-
scriptive data are expressed as Mean± SD and 
frequency distribution. For correlations Spear-
man’s rho test was used. All statistical analyses 
were performed using the SPSS (version 11.00) 
software and statistical signiﬁcance was inferred 
at a p value< 0.05. 
4. Results
 The  total subjects were 95(F =61, M =34) 
eHT patients. The mean ± SD of  ages of  hyper-
tensive group was 57±12 years. In  eHT patients, 
eGFR was 87±17.8 cc/min. Duration of  HTN 
in patients were 5.5±4.5 years. In eHT patients, 
serum  Lp(a) was 51±20mg/dL. There was no 
signiﬁcant association between Lp(a) and stages 
of  hypertension (p>0.05). In eHT patients an in-
verse correlation between seum Lp(a) and crae-
tinin clearance was seen (r=-0.175 p<0.05). There 
was a signiﬁcant positive correlation between se-
rum  Lp(a) and age in  eHT patients (r=0.191 
p<0.05) or duration of  HTN (known as duration 
of  hypertension period) (r=0.362  p<0.05).
5. Discussion
 In this study we found,  no signiﬁcant associa-
tion between Lp(a) and stages of  hypertension. 
In patients, an inverse correlation between seum 
Lp(a) with craetinin clearance was seen. Also, 
there was not any signiﬁcant positive correlation 
between serum  Lp(a) and ages  of  hypertensive 
patients or duration of  HTN (known as duration 
of  hypertension period). To measure the serum 
concentrations of  Lp(a) in a group of  essential 
hypertensive patients not receiving pharmacolog-
ical treatment and with no clinical signs of  associ-
ated pathologies or organ damage, Catalano et al. 
conducted a study on123 Caucasian eHT patients 
(47 men and 76 women) (6). They found that the 
hypertensive patients had higher plasma concen-
trations of  Lp(a), total cholesterol, TG and very 
low density lipoprotein than controls with no dif-
ferences in the plasma concentrations of  Lp(a) 
between the two sexes (6). To evaluate Lp (a) in 
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HTN, Bhavani et al. studied a group of  eHT pa-
tients, who were not receiving pharmacological 
treatment and with no clinical signs of  associated 
illness or organ damage. The study contained 37 
eHT patients (27 men and 10 women) and com-
pared with 50 controls (32 men and 18 women). 
It was observed that the hypertensive patients 
had higher plasma concentrations of  Lp (a), and 
Lp (a) values which were correlated signiﬁcantly 
with systolic blood pressure (SBP) diastolic blood 
pressure (DBP). They showed that elevated 
plasma Lp (a) levels were associated with hyper-
tension (7). They concluded that higher plasma 
concentrations of  Lp (a), albeit with in the nor-
mal range, could be an independent risk factor 
for atherosclerosis, and could contribute towards 
increasing the risk for cardiovascular diseases in 
persons with essential hypertension (7). To inves-
tigate whether or not Lp(a) levels is a  predictor 
of  coronary heart disease (CHD) in patients with 
essential hypertension, Gazzaruso et al. conduct-
ed a study in 249 patients with eHTN and in 142 
non-hypertensive patients with CHD as well as in 
264 healthy controls (8). The study showed that, 
Lp(a) levels did not differ signiﬁcantly between 
hypertensive and non-hypertensive patients with 
CHD. However, stepwise regression analysis in-
dicated that high Lp(a) level is a strong predictor 
of  CHD in hypertensive patients (8). Likewise, 
Antonicelli et al. investigated the correlation be-
tween blood pressure levels and plasma Lp(a) 
concentration, in patients with eHTN. The study 
was performed in 54 untreated hypertensive pa-
tients whose blood pressures were monitored for 
24 h by ambulatory blood pressure monitoring. A 
signiﬁcant correlation was found between Lp(a) 
levels and the night-time systolic or diastolic 
pressures, as well as between the mean night-time 
fall in systolic and diastolic blood pressures (3).
6. Conclusions
 Our data suggest that Lp(a), as a cofactor 
in essential hypertension, may be involved  in a 
mechanism that remains to be elucidated.
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